Technical Analysis for RGEN - Repligen Corporation
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Up | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Overbought Stochastic | Strength | 0.00% | |
| Gapped Down | Weakness | 0.00% | |
| Doji - Bearish? | Reversal | -1.30% | |
| Multiple of Ten Bullish | Other | -1.30% | |
| Outside Day | Range Expansion | -1.30% | |
| Overbought Stochastic | Strength | -1.30% | |
| NR7 | Range Contraction | -1.36% | |
| NR7-2 | Range Contraction | -1.36% | |
| Narrow Range Bar | Range Contraction | -1.36% | |
| Stochastic Reached Overbought | Strength | -1.36% |
| Alert | Time |
|---|---|
| Fell Below Previous Day's Low | about 15 hours ago |
| Down 2 % | about 15 hours ago |
| Gap Down Partially Closed | about 16 hours ago |
| Gapped Down (Partial) | about 16 hours ago |
| Down 1% | about 16 hours ago |
Get a Trading Assistant
- Earnings date: 11/12/2024
Repligen Corporation Description
Repligen Corporation, a life sciences company, engages in the development, production, and commercialization of consumable products used in the process of manufacturing biological drugs. Its bioprocessing products are sold to various life sciences and biopharmaceutical companies worldwide. The company manufactures Protein A, a critical reagent used to separate and purify monoclonal antibody therapeutics. It also supplies various growth factor products used to increase cell culture productivity during the fermentation stage of drug manufacturing. In addition, the company develops and markets its OPUS brand series of pre-packed ‘plug-and-play' chromatography columns, and provides ELISA test kits to ensure final product quality. Further, Repligen has a portfolio of clinical-stage partnering assets, including a pancreatic imaging agent in Phase 3 development and a orphan drug candidate in Phase 1 development. The company was founded in 1981 and is headquartered in Waltham, Massachusetts.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Life Sciences Natural Sciences Monoclonal Antibody 3 D Orphan Drug Consumable Products Imaging Agent Chromatography Bioprocessing Cell Culture Bioprocess Drug Manufacturing Growth Factor Products
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 211.13 |
| 52 Week Low | 113.5 |
| Average Volume | 619,586 |
| 200-Day Moving Average | 154.05 |
| 50-Day Moving Average | 141.16 |
| 20-Day Moving Average | 142.48 |
| 10-Day Moving Average | 144.40 |
| Average True Range | 6.23 |
| RSI (14) | 56.71 |
| ADX | 19.17 |
| +DI | 32.34 |
| -DI | 19.61 |
| Chandelier Exit (Long, 3 ATRs) | 135.79 |
| Chandelier Exit (Short, 3 ATRs) | 140.21 |
| Upper Bollinger Bands | 158.48 |
| Lower Bollinger Band | 126.49 |
| Percent B (%b) | 0.69 |
| BandWidth | 22.45 |
| MACD Line | 2.30 |
| MACD Signal Line | 0.88 |
| MACD Histogram | 1.4252 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 154.26 | ||||
| Resistance 3 (R3) | 154.06 | 151.93 | 153.30 | ||
| Resistance 2 (R2) | 151.93 | 150.47 | 152.04 | 152.98 | |
| Resistance 1 (R1) | 150.22 | 149.56 | 149.16 | 150.42 | 152.66 |
| Pivot Point | 148.09 | 148.09 | 147.56 | 148.20 | 148.09 |
| Support 1 (S1) | 146.38 | 146.63 | 145.32 | 146.58 | 144.34 |
| Support 2 (S2) | 144.25 | 145.72 | 144.36 | 144.02 | |
| Support 3 (S3) | 142.54 | 144.25 | 143.70 | ||
| Support 4 (S4) | 142.74 |
